These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 22372946)
1. Complement activation in thrombotic thrombocytopenic purpura. Réti M; Farkas P; Csuka D; Rázsó K; Schlammadinger Á; Udvardy ML; Madách K; Domján G; Bereczki C; Reusz GS; Szabó AJ; Prohászka Z J Thromb Haemost; 2012 May; 10(5):791-8. PubMed ID: 22372946 [TBL] [Abstract][Full Text] [Related]
2. Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura. Mikes B; Sinkovits G; Farkas P; Csuka D; Rázsó K; Réti M; Radványi G; Demeter J; Prohászka Z Thromb Haemost; 2016 May; 115(5):1034-43. PubMed ID: 26763086 [TBL] [Abstract][Full Text] [Related]
3. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura. Thomas MR; de Groot R; Scully MA; Crawley JT EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702 [TBL] [Abstract][Full Text] [Related]
4. Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade. Bitzan M; Hammad RM; Bonnefoy A; Al Dhaheri WS; Vézina C; Rivard GÉ Pediatr Nephrol; 2018 Aug; 33(8):1437-1442. PubMed ID: 29728803 [TBL] [Abstract][Full Text] [Related]
5. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification. Shenkman B; Einav Y Autoimmun Rev; 2014; 13(4-5):584-6. PubMed ID: 24418304 [TBL] [Abstract][Full Text] [Related]
7. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Mannucci PM; Cugno M Thromb Res; 2015 Nov; 136(5):851-4. PubMed ID: 26386489 [TBL] [Abstract][Full Text] [Related]
8. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Mori Y; Wada H; Gabazza EC; Minami N; Nobori T; Shiku H; Yagi H; Ishizashi H; Matsumoto M; Fujimura Y Transfusion; 2002 May; 42(5):572-80. PubMed ID: 12084165 [TBL] [Abstract][Full Text] [Related]
9. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285 [TBL] [Abstract][Full Text] [Related]
10. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. Plaimauer B; Kremer Hovinga JA; Juno C; Wolfsegger MJ; Skalicky S; Schmidt M; Grillberger L; Hasslacher M; Knöbl P; Ehrlich H; Scheiflinger F J Thromb Haemost; 2011 May; 9(5):936-44. PubMed ID: 21294825 [TBL] [Abstract][Full Text] [Related]
11. Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura. Li D; Xiao J; Paessler M; Zheng XL Thromb Haemost; 2011 Nov; 106(5):947-58. PubMed ID: 21901237 [TBL] [Abstract][Full Text] [Related]
13. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Furlan M; Lämmle B Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108 [TBL] [Abstract][Full Text] [Related]
14. Recent advances in thrombotic thrombocytopenic purpura. Sadler JE; Moake JL; Miyata T; George JN Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695 [TBL] [Abstract][Full Text] [Related]
15. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity]. Kato S; Fujimura Y Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861 [TBL] [Abstract][Full Text] [Related]
16. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. Starke R; Machin S; Scully M; Purdy G; Mackie I Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414 [TBL] [Abstract][Full Text] [Related]
17. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Tsai HM; Raoufi M; Zhou W; Guinto E; Grafos N; Ranzurmal S; Greenfield RS; Rand JH Thromb Haemost; 2006 May; 95(5):886-92. PubMed ID: 16676082 [TBL] [Abstract][Full Text] [Related]
18. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Furlan M; Robles R; Solenthaler M; Lämmle B Blood; 1998 Apr; 91(8):2839-46. PubMed ID: 9531594 [TBL] [Abstract][Full Text] [Related]